Lumateperone: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Expand Lumateperone with Stahl-sourced detail (with skepticism) |
Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
| brand = Caplyta | | brand = Caplyta | ||
| classes = Atypical antipsychotic, 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity | | classes = Atypical antipsychotic, 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity | ||
| mechanism = Very high affinity 5HT2A receptor antagonism (~50-fold higher affinity than for D2). Moderate D2 receptor activity proposed to be differential between presynaptic (partial agonist) and postsynaptic (antagonist) | | mechanism = Very high affinity 5HT2A receptor antagonism (~50-fold higher affinity than for D2). Moderate D2 receptor activity proposed to be differential between presynaptic (partial agonist) and postsynaptic (antagonist), if confirmed, this would explain why lumateperone has antipsychotic efficacy at D2 occupancy lower than other antipsychotics. Moderate SERT inhibition (suggests antidepressant potential). | ||
| uses = Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). | | uses = Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). | ||
| starting_dose = 42 mg PO once daily with food (no titration) | | starting_dose = 42 mg PO once daily with food (no titration) | ||
| Line 14: | Line 14: | ||
| pregnancy = Limited data; National Pregnancy Registry for Atypical Antipsychotics | | pregnancy = Limited data; National Pregnancy Registry for Atypical Antipsychotics | ||
| legal = Rx | | legal = Rx | ||
| intro = '''Lumateperone''' (brand name Caplyta) is an atypical antipsychotic FDA-approved in 2019 for schizophrenia and in 2021 for bipolar depression. Its receptor profile combines very high 5HT2A antagonist affinity with moderate D2 activity that is hypothesized to be differential between pre- and post-synaptic compartments | | intro = '''Lumateperone''' (brand name Caplyta) is an atypical antipsychotic FDA-approved in 2019 for schizophrenia and in 2021 for bipolar depression. Its receptor profile combines very high 5HT2A antagonist affinity with moderate D2 activity that is hypothesized to be differential between pre- and post-synaptic compartments, proposed mechanism is presynaptic D2 partial agonism (reducing DA release) plus postsynaptic D2 antagonism. If this differential is real, it explains efficacy at lower D2 occupancy and the favorable metabolic/motor side effect profile observed clinically. Stahl emphasizes this mechanism story; primary evidence is still preliminary. | ||
Lumateperone also has moderate SERT inhibition (mood-relevant), explaining its bipolar depression efficacy. Among atypicals, it has notably low rates of weight gain, metabolic syndrome, prolactin elevation, akathisia, and parkinsonism in trials. | Lumateperone also has moderate SERT inhibition (mood-relevant), explaining its bipolar depression efficacy. Among atypicals, it has notably low rates of weight gain, metabolic syndrome, prolactin elevation, akathisia, and parkinsonism in trials. | ||
| Line 22: | Line 22: | ||
}} | }} | ||
[[Category:Second-generation neuroleptics]] | |||
[[Category:Second- | |||
[[Category:Neuroleptics]] | [[Category:Neuroleptics]] | ||
[[Category:Atypical Antipsychotics]] | [[Category:Atypical Antipsychotics]] | ||
[[Category:5HT2A Antagonists]] | [[Category:5HT2A Antagonists]] | ||
[[Category:Psychotic Disorders]] | [[Category:Psychotic Disorders]] | ||
[[Category:Mood | [[Category:Mood stabilizers]] | ||